Kodiak Sciences Inc. (KOD)
8.25
0.65 (8.55%)
At close: Jan 15, 2025, 11:48 AM
undefined% (undefined)
| Bid | 8.21 |
| Market Cap | 434.15M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.64 |
| PE Ratio (ttm) | -2.27 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 8.27 |
| Volume | 287,087 |
| Avg. Volume (20D) | 447,796 |
| Open | 7.80 |
| Previous Close | 7.60 |
| Day's Range | 7.63 - 8.47 |
| 52-Week Range | 2.19 - 11.60 |
| Beta | undefined |
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, a...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 4, 2018
Employees 111
Stock Exchange NASDAQ
Ticker Symbol KOD
Website https://kodiak.com
Analyst Forecast
According to 4 analyst ratings, the average rating for KOD stock is "Hold." The 12-month stock price forecast is $4, which is a decrease of -51.52% from the latest price.
Buy 25.00%
Hold 50.00%
Sell 25.00%
1 month ago ·
Source
+29.63%
Kodiak Sciences shares are trading higher after Je...
Unlock content with
Pro Subscription
9 months ago ·
Source
-29.4%
Kodiak Sciences shares are trading lower after the company reported worse-than-expected Q4 EPS results.
